Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 5, 2002. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Shares (ADSs), specifically regarding grants made under the company's equity incentive plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and equity grants rather than consolidated financial performance.
Material Changes
On December 3, 2002, the following equity awards were granted to directors:
- Performance Share Plan (Target Awards):
- Dr. J-P Garnier: 70,000 Ordinary Shares
- Mr. J D Coombe: 40,000 Ordinary Shares
- Share Option Plan:
- Dr. J-P Garnier: 450,000 Ordinary Shares (Subscription Price: $37.25)
- Mr. J D Coombe: 290,000 Ordinary Shares (Subscription Price: £11.79)
The filing notes that these awards were granted at the same level as the previous year.
Outlook, Risks, and Management Commentary
Performance Conditions: The Target Awards granted on December 3, 2002, are subject to a three-year measurement period commencing January 1, 2003, and ending December 31, 2005. Vesting of the Share Options is also subject to a performance condition.
Plan Approval: Both the Performance Share Plan and the Share Option Plan were approved by shareholders on July 31, 2000.
The filing does not contain specific guidance, risk factors, or unusual items beyond the standard terms of the equity plans.
Investor Verification Checklist
- Verify the exact number of ADSs granted, as the text lists Ordinary Shares for Target Awards but implies ADS equivalents exist (1 ADS = 2 Ordinary Shares).
- Confirm the specific performance metrics required for the vesting of the 2002 Share Options and Target Awards.
- Review the full 2002 annual report (Form 20-F) for consolidated financial results, as this 6-K does not contain them.
- Check the current share price relative to the subscription prices of $37.25 and £11.79 to assess the intrinsic value of the options.